Immune system activation via Bacillus Calmette–Guérin stimulation

"Immune system activation via Bacillus Calmette–Guérin stimulation" refers not to a discrete molecular target but rather to a complex set of **immunological processes** triggered by exposure to the live attenuated bacterium *Mycobacterium bovis* BCG. Upon administration—either as a vaccine for tuberculosis or as an intravesical therapy for bladder cancer—BCG interacts primarily with innate immune cells at the site of inoculation. Macrophages and dendritic cells phagocytose the bacteria through various pattern recognition receptors including Toll-like receptors and NOD-like receptors. This leads to their maturation into potent antigen-presenting cells that upregulate co-stimulatory molecules such as CD80/CD86 and present antigens on MHC molecules, thereby priming both CD4+ and CD8+ T cell responses.[1][7] BCG also induces "trained immunity," an epigenetically mediated enhancement in the responsiveness of innate immune cells like monocytes/macrophages. This results in increased production of inflammatory cytokines such as TNF‑α, IL‑1β, IL‑12 upon subsequent encounters with unrelated pathogens.[3][6] In addition to adaptive responses involving T helper type 1 differentiation and cytotoxic lymphocyte activity,[2] NK cell cytotoxicity is enhanced by monocyte-derived cytokines following BCG stimulation.[5] These mechanisms underlie both its protective effect against tuberculosis infection—as well as heterologous protection against other infections—and its efficacy as an anti-tumor agent. Because this entry describes a **process/pathway** rather than a specific molecular entity like a receptor or enzyme, it is not considered a canonical therapeutic target per se; thus "is_target" should be marked false. The entry is also "incorrect" for structured drug-target databases focused on discrete biomolecules.

Other names

BCG-induced immune activationBacillus Calmette–Guérin-mediated immune responseBCG immunostimulationTrained immunity via BCG

Induction of trained innate immunity through epigenetic reprogramming of monocytes/macrophages. Enhanced cytokine production upon secondary challenge with unrelated pathogens. Activation of antigen-presenting cells leading to T cell priming and differentiation into Th1/Th17 phenotypes. Stimulation of natural killer cells via monocyte-derived cytokines such as IL‑12 and IFN‑α.